Emerging high-risk ST101 and ST307 carbapenem-resistant Klebsiella pneumoniae clones from bloodstream infections in Southern Italy.
Adolescent
Adult
Aged
Aged, 80 and over
Bacterial Proteins
/ genetics
Child
Child, Preschool
Drug Resistance, Multiple, Bacterial
/ genetics
Electrophoresis, Gel, Pulsed-Field
Female
Humans
Infant
Infant, Newborn
Italy
/ epidemiology
Klebsiella Infections
/ epidemiology
Klebsiella pneumoniae
/ enzymology
Male
Middle Aged
Molecular Epidemiology
Multilocus Sequence Typing
Prospective Studies
Real-Time Polymerase Chain Reaction
Serogroup
Whole Genome Sequencing
Young Adult
beta-Lactamases
/ genetics
Bloodstream infections
Carbapenem-resistant Klebsiella pneumoniae
Drug resistance
Resistome
ST101
ST307
Virulome
Whole genome sequencing
Journal
Annals of clinical microbiology and antimicrobials
ISSN: 1476-0711
Titre abrégé: Ann Clin Microbiol Antimicrob
Pays: England
ID NLM: 101152152
Informations de publication
Date de publication:
01 Jun 2020
01 Jun 2020
Historique:
received:
03
01
2020
accepted:
25
05
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Carbapenem-resistant Klebsiella pneumoniae (CR-KP) is an urgent public health issue in Italy. This pattern of resistance is due mainly to dissemination of carbapenemase genes. Molecular characterization of carbapenem-resistant Klebsiella pneumoniae (CR-KP) strains was performed over a three-year period. In-depth analysis was performed on a subset of emerging CR-KP ST101 and ST307 clones. A prospective study was performed on 691 patients with CR-KP bloodstream infections hospitalized in 19 hospitals located in three large provinces in Southern Italy. Carbapenemase genes were identified via genotyping methods. Multi-locus sequence typing (MLST) and Whole Genome Sequencing (WGS) were carried out on ST101 and ST307 isolates. Among the CR-KP isolates, bla ST512 is widespread in Southern Italy, but ST101 and ST307 are emerging since they were found in a significant proportion of cases. Aggressive infection control measures and a continuous monitoring of these high-risk clones are necessary to avoid rapid spread of CR-KP, especially in hospital settings.
Sections du résumé
BACKGROUND
BACKGROUND
Carbapenem-resistant Klebsiella pneumoniae (CR-KP) is an urgent public health issue in Italy. This pattern of resistance is due mainly to dissemination of carbapenemase genes. Molecular characterization of carbapenem-resistant Klebsiella pneumoniae (CR-KP) strains was performed over a three-year period. In-depth analysis was performed on a subset of emerging CR-KP ST101 and ST307 clones.
METHODS
METHODS
A prospective study was performed on 691 patients with CR-KP bloodstream infections hospitalized in 19 hospitals located in three large provinces in Southern Italy. Carbapenemase genes were identified via genotyping methods. Multi-locus sequence typing (MLST) and Whole Genome Sequencing (WGS) were carried out on ST101 and ST307 isolates.
RESULTS
RESULTS
Among the CR-KP isolates, bla
CONCLUSIONS
CONCLUSIONS
ST512 is widespread in Southern Italy, but ST101 and ST307 are emerging since they were found in a significant proportion of cases. Aggressive infection control measures and a continuous monitoring of these high-risk clones are necessary to avoid rapid spread of CR-KP, especially in hospital settings.
Identifiants
pubmed: 32487201
doi: 10.1186/s12941-020-00366-y
pii: 10.1186/s12941-020-00366-y
pmc: PMC7266126
doi:
Substances chimiques
Bacterial Proteins
0
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Références
PLoS One. 2015 Jul 15;10(7):e0132936
pubmed: 26177547
BMC Infect Dis. 2017 Oct 10;17(1):666
pubmed: 29017452
Microb Drug Resist. 2013 Aug;19(4):295-7
pubmed: 23530541
Int J Med Microbiol. 2013 Aug;303(6-7):298-304
pubmed: 23499304
FEMS Microbiol Rev. 2017 May 1;41(3):252-275
pubmed: 28521338
Genome Announc. 2016 Apr 07;4(2):
pubmed: 27056222
Microb Genom. 2017 Apr 26;3(4):e000110
pubmed: 28785421
Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1687-1691
pubmed: 31165962
PLoS One. 2018 Jun 8;13(6):e0198526
pubmed: 29883490
Emerg Infect Dis. 2014 Nov;20(11):1812-20
pubmed: 25341126
BMC Microbiol. 2015 Nov 09;15(1):260
pubmed: 26552763
Euro Surveill. 2013 May 30;18(22):
pubmed: 23787077
Front Microbiol. 2019 Apr 02;10:542
pubmed: 31001209
J Antimicrob Chemother. 2016 Dec;71(12):3392-3399
pubmed: 27530752
BMC Infect Dis. 2019 Nov 4;19(1):928
pubmed: 31684890
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29507071
Antimicrob Resist Infect Control. 2017 Jan 7;6:5
pubmed: 28074126
BMC Gastroenterol. 2011 Sep 30;11:103
pubmed: 21961811
Euro Surveill. 2019 Jan;24(5):
pubmed: 30722813
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5612-5
pubmed: 27401575
Euro Surveill. 2012 Aug 16;17(33):
pubmed: 22913976
Clin Microbiol Infect. 2014 Apr;20(4):350-4
pubmed: 23927757
Int J Immunopathol Pharmacol. 2013 Jul-Sep;26(3):785-90
pubmed: 24067478
J Antimicrob Chemother. 2016 Dec;71(12):3386-3391
pubmed: 27585968
J Clin Microbiol. 2005 Aug;43(8):4178-82
pubmed: 16081970
J Hosp Infect. 2018 Aug;99(4):413-418
pubmed: 29621600
J Clin Microbiol. 2013 Oct;51(10):3176-82
pubmed: 23850951
Clin Infect Dis. 2012 Oct;55(7):943-50
pubmed: 22752516
Clin Microbiol Infect. 2015 Mar;21(3):e15-7
pubmed: 25658574
APMIS. 2017 May;125(5):491-498
pubmed: 28295617
Antimicrob Agents Chemother. 2014 Jul;58(7):3895-903
pubmed: 24777092
J Clin Microbiol. 2009 Nov;47(11):3793-4
pubmed: 19759220
Gut Pathog. 2012 Jul 16;4(1):7
pubmed: 22800501
Adv Microb Physiol. 2017;70:261-313
pubmed: 28528649
Infect Control Hosp Epidemiol. 2009 Oct;30(10):972-6
pubmed: 19712030
Clin Microbiol Infect. 2011 Sep;17(9):1444-7
pubmed: 21668577
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7494-7497
pubmed: 27645236
Int J Antimicrob Agents. 2016 Dec;48(6):583-591
pubmed: 27524102
Clin Microbiol Infect. 2014 Oct;20(10):O633-5
pubmed: 24476498